The combined results showed that the use of mTOR inhibitors had a tendency to increase the risk of developing FAEs among patients with renal cell cancer (RR, 3.01; 95% CI, 0.67 to 13.47; P = 0.15), breast cancer (RR, 2.00; 95% CI, 0.26 to 15.23; P = 0.50), and neuroendocrine tumors (RR, 2.00; 95% CI, 0.20 to 20.15; P = 0.56), although the difference was not statistically significant (table 2). Here, MTOR is linked to neuroendocrine neoplasm.